5.08 0.00 (0.00%)
After hours: 4:27PM EST
|Bid||4.00 x 100|
|Ask||5.35 x 300|
|Day's Range||4.86 - 5.10|
|52 Week Range||4.01 - 8.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 2, 2018 - May 7, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.56|
Keryx Biopharmaceuticals Inc (NASDAQ:KERX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
Stock Monitor: Keryx Biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free earnings report on Illumina, Inc. (NASDAQ: ILMN ). If ...
On a per-share basis, the Boston-based company said it had a loss of 26 cents. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Fourth quarter 2017 total revenues of $18.7 million, including net U.S. Auryxia ® product sales of $17.3 million Full year 2017 total revenues of $60.6 million; net U.S. Auryxia product sales more than ...
BOSTON, Feb. 02, 2018-- Keryx Biopharmaceuticals, Inc., a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced that it will host a conference ...
NEW YORK, NY / ACCESSWIRE / January 15, 2018 / U.S. markets closed at record highs Friday, posting weekly gains, on investor optimism over the current earnings season. The Dow Jones Industrial Average ...
Investors in Keryx Biopharmaceuticals (KERX) need to pay close attention to the stock based on moves in the options market lately.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Keryx Biopharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to KERX-US. Comparing the performance and risk of Keryx Biopharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
BOSTON, Dec. 22, 2017-- Keryx Biopharmaceuticals, Inc,, a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced it will webcast its corporate ...
Categories: Yahoo FinanceGet free summary analysis Keryx Biopharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Keryx Biopharmaceuticals, Inc. – Ardelyx, Inc., AMAG Pharmaceuticals, Inc., Impax Laboratories, Inc., Apricus Biosciences, Inc., Sophiris Bio Inc., Momenta Pharmaceuticals, Inc., VIVUS, Inc. and Aeterna Zentaris Inc. (ARDX-US, ... Read more (Read more...)
NEW YORK, Nov. 29, 2017-- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ...
Shares took a nosedive after the company's earnings report, but with a new FDA approval under its belt, this could be a buying opportunity for investors.
NEW YORK, NY / ACCESSWIRE / November 13, 2017 / U.S. markets slumped this week, breaking the Dow's streak of 8 consecutive weekly gains, on concerns of a delay in the rollout of President Trump's much ...
The much-maligned drugmaker is making progress, but it's not out of the woods yet. Plus, why Keryx Pharmaceuticals shares tumbled despite winning a key FDA approval.
Keryx Biopharmaceuticals (NASDAQ:KERX) has commercial adoption challenges ahead for its iron deficiency anemia asset Auryxia, says Cowen analyst Boris Peaker. After the company's drug came up short of the Street to the tune of a $3.6 million miss, slowing prescription growth does not fire up confidence for shareholders.
While focus remained on Regeneron's (REGN) Q3 earnings, Dicerna was also in the news related to its collaboration agreement with Boehringer Ingelheim.
Research Desk Line-up: Array BioPharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 9, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...